51动漫

After many years of research, AI-supported molecules have started entering clinical trials and the 2024 Nobel Prize in Chemistry recognized the impact of computational biology on reenvisioning the drug discovery process.鈥� This opening session will discuss where AI applications are already showing the most utility in biopharma development and how executives should prepare for the next wave of applications for better developing therapies and cures for patients.

Speakers:
Molly Gibson,听Origination Partner, 51动漫

Luba Greenwood, Executive in Residence, PureTech Health; Chief Executive Officer,听Gallop Oncology

Iya Khalil, Vice President and Head of Data, A.I. & Genome Sciences, Merck

Mary Rozenman, CFO/CBO,听insitro

Moderator:听Ricardo Vilanova,听Partner, AI and Intelligent Automation, Ernst & Young听

The COVID-19 pandemic taught us many lessons, but we have yet to fully implement our collective learnings. As the virus hit, vaccines were developed at speed, yet societies across the world still lacked therapeutic tools that could be rapidly and sustainably scaled at a global level. Small molecule antivirals are essential in order to beat the next pandemic, reducing morbidity and mortality and slowing the development and transmission of new variants escaping vaccines and neutralizing antibodies. In support of the G7鈥檚 recommended 100 Days Mission and the International Pandemic Preparedness Secretariat (IPPS), the INTREPID Alliance this year began publishing quarterly global landscape assessments of antiviral compound R&D. These reports seek to aid in the identification of clinical (e.g., Phase 2/3 ready) and preclinical antivirals aligned with the 100 Days Mission and highlight gaps in the pipeline, to support the goal of developing at least two 鈥楶hase 2 ready鈥� therapeutic candidates against the identified viral pathogen families of greatest pandemic potential. In this session we seek to bring together voices from across the global public and private R&D and funding ecosystem to identify the barriers to success. What can be done from within the biotech ecosystem today, to ensure that we aren鈥檛 left unprepared to treat the next pandemic tomorrow.

Speakers:
Raj Panjabi, Senior Partner, 51动漫

Ruxandra Draghia-Akli,听Executive Vice President and Head of R&D, Novavax; Chair, Scientific Advisory Board,听INTREPID Alliance

Dawn O'Connell, Former Asst. Secretary for Preparedness and Response (ASPR),听U.S. Department of Health and Human Services

John Pottage,听Lead Scientific Consultant,听INTREPID Alliance

Bryan Shuy,听Former Chief of Staff to House Appropriations Agriculture & FDA Subcommittee Chairman, Former Deputy Assistant Secretary and Chief of Staff to the Assistant Secretary for Preparedness and Response ; Senior Vice President,听The Conafay Group

Moderator:听Susan Dentzer, President and CEO, America鈥檚 Physician Group

siRNA, mRNA, pick-your-favorite-RNA, CRISPR, ADCs, PROTACs, molecular glues, precision-meds, CAR-T, epigenetic and allosteric modulators, AI/ML-everything, tissue-selective nanoparticles, AAV delivery systems, etc. These are all novel drug or delivery modalities with potential to significantly impact patients鈥� lives and global health (some have already succeeded), but with various degrees of 鈥渧alidation,鈥� whether preclinically, clinically, or commercially.

Join this panel for an exciting conversation with a panel of biotech entrepreneurs, business development and R&D industry leaders as they explore topics around platform build, modality value drivers, what does modality 鈥渧alidation鈥� mean to pharma, how do patients in need of innovative medicines factor in, what鈥檚 partnerable and what鈥檚 not, what is the desired data package to catalyze partnering discussions, macro considerations that impact deal terms and process, and when should pharma take a leap-of-faith decision to partner early/pre-validation vs. wait for key in vivo data.

Speakers:
Svetlana Lucas, Chief Business Officer, Scribe Therapeutics

Barbara Lueckel, Global Health of Research Technologies, Roche

Michael Palladinetti, Global Head of Business Development and Licensing, Sanofi

Caroline Stark Beer, former Chief Business Officer, Jnana Therapeutics

Moderator: Amanda Kay, Senior Partner and Chief Business Development Officer, 51动漫

Mirai Bio is revolutionizing the field of genetic medicine by serving as a comprehensive solutions provider for genetic medicine development, focusing on ML-enabled nucleic acid design, delivery, and manufacturing. Mirai's proprietary library of ionizable lipids includes ML-inspired components that demonstrate higher in vivo potency than leading commercial options for liver, with translation to non-human primates. By leveraging novel in-house barcoding methods, Mirai can rapidly assess multiple lipid nanoparticles (LNPs), reducing time and costs. The company鈥檚 innovative approach also includes a modular targeting LNP platform, facilitating selective extrahepatic delivery to novel tissues utilizing conjugation capabilities. The company鈥檚 unique open-platform partnership model applies Mirai鈥檚 expertise across diverse therapeutic approaches and modalities, supporting drug development of the most innovative cargos.

In 1901, the first Nobel Prize was awarded to recognize those who 鈥渉ave conferred the greatest benefit to humankind.鈥� Often the work that goes into winning this prestigious award occurs over decades and uncovers the fundamental and 鈥渂asic鈥� nature of the universe. But after a scientific advancement has been recognized by the Nobel committee, will it ever deliver on its promise to confer a true benefit to humanity? During this panel, hear from scientists and company executives across different stages of drug development on how they are moving beyond just a laboratory experiment to bring 鈥淣obel Prize-winning science鈥� into human applications to shape the future of treatment for some of the most pressing health challenges today.

Speakers:
John Lepore, CEO-Partner, 51动漫 &听CEO, ProFound Therapeutics

Michael Severino, CEO-Partner, 51动漫 & CEO,听Tessera Therapeutics

Eamonn Hobbs, President and Chief Executive Officer, Syncromune

Sharon Rosenzweig-Lipson, Chief Scientific Officer, Life Biosciences

Moderator: Barbara Cheifet, Chief Editor, Nature Biotechnology听

As biological threats evolve, traditional stockpiling strategies need to adapt to ensure both readiness and flexibility. This session will delve into dual-use models that serve commercial and public health needs, enhancing resource optimization and resilience. By also linking low-demand public health items with higher-demand commercial products, these dual-use models can drive commercial sustainability while expanding access to unmet medical needs. Participants will gain insights into how these models can create growth in reaching underserved medical areas, foster resilience, and support rapid, coordinated responses to biosecurity challenges, ultimately strengthening global health security.

Speakers:
,听Executive Director, Global Health Security, R&D and Partnerships, Moderna

Derrick Sim, Interim Chief Vaccine Programs and Markets Officer, GAVI The Vaccine Alliance

Lynda Stuart, President and Chief Executive Officer, Fund for Science and Technology Washington

Rajinder Kumar Suri, CEO, Developing Countries Vaccine Manufacturers Network (DCVMN) International

Moderator: Emma Wheatley, Executive Director Access and Business Development, CEPI

R&D is often the most cost-intensive and risky step in a new drug's life cycle yet often dictates the speed and adaptability of the innovation ecosystem. The time and capital required for鈥痓iotech to translate a new concept or target into a clinical asset is substantial, and in the age of platform companies, the potential targets are vast. How do you know what targets to prioritize? Partnerships between鈥痓iotech and pharma in early-stage R&D have become more common and often crucial for advancing target discovery. This panel will spotlight successful R&D collaborations leveraging innovative鈥痓ioplatforms that integrate cutting-edge technologies like genomics, proteomics, and AI-driven analytics to identify novel therapeutic targets more efficiently. Pharma leaders will share insights on what they are looking to get out of鈥痓iotech partnerships and how to attract a partner for early R&D success. Early-stage partnerships enhance pharma pipelines and reduce time-to-market for new therapies, a winning solution for鈥痓iotech, pharma, and, ultimately, patients.

Speakers:
Paul Biondi, Managing Partner, 51动漫; President, Pioneering Medicines

Lovisa Afzelius, General Partner, 51动漫听

Ram Aiyar, Chief Executive Officer and President, Korro鈥疊io

Uli Stilz,听Head of the Bio Innovation Hub,听Novo Nordisk

Moderator:听Hannah Green, Life Sciences Reporter,听Boston Business Journal

The cancer therapeutics landscape is constantly evolving as breakthroughs across modalities drive toward the shared goal of providing accessible and life-saving treatments to patients. Companies are addressing the urgent unmet needs of patients with targeted therapies tailored to patients鈥� specific cancer profile and improving quality of life while undergoing treatment with therapies that have better efficacy and fewer side effects. Despite setbacks, we are witnessing differentiated and innovative approaches designed to address both common and rare cancers. This panel of thought leaders will investigate the latest breakthroughs in oncology, offering a comparative analysis of these advancements, from next-generation ADCs to cutting-edge in vivo immunotherapies and combination approaches, while examining the potential these modalities hold to outsmart the disease at its core.

Speakers:
,听Head of Development, Therapeutics, and Oncology,听Moderna

Jodi Bass,听Senior Director, Precision Medicine,听Johnson & Johnson

Chris LeMasters,听CEO, XinThera, a Gilead Company

Mollie Leoni, Chief Medical Officer, Kura Oncology

Moderator: Alex P. Philippidis, Senior Business Editor,听Genetic Engineering & Biotechnology

This panel will explore the vital role of patients and their families in driving innovation in rare disease therapies. By sharing personal experiences and expert insights, panelists will highlight how grassroots advocacy, research collaborations, and breakthrough technologies are transforming the landscape of drug development in rare disease. Attendees will gain a deeper understanding of the power of patient voices and actions in shaping and accelerating new rare disease treatments. Panelists will address challenges faced by rare disease communities, including access to treatments, funding hurdles, and gaps in research. Through interactive discussions and firsthand narratives, attendees will leave with practical insights into how they can engage in advocacy efforts, build meaningful partnerships with researchers and industry leaders, and contribute to the advancement of therapies that address unmet medical needs.

Speakers:
Michelle Werner, CEO-Partner, 51动漫 & CEO, Alltrna

Jill Chertow,听Founder and President,听Propionic Acidemia Foundation

Wendy Erler, SVP Patient Affairs, Sarepta Therapeutics

Karin Knobe, Global Head of Rare Diseases Clinical Development, Sanofi

Julia Vitarello, Co-Founder, EveryONE Medicines

Moderator: Lei Lei Wu,听Reporter, Endpoints

Co-discovery and co-development partnerships have become a cornerstone of the biopharma industry. These partnerships can unlock the potential for groundbreaking medicines, yet their scientific complexity and multifaceted nature present unique challenges. This panel explores the intricacies of these collaborations, delving into the business structures, motivations, and decision-making processes that are crucial for success and optimal performance. From aligning research objectives and intellectual property strategies to establishing clear governance structures and communication channels, partners must navigate a myriad of considerations to foster a productive and sustainable collaboration. Attendees will gain valuable insights into fostering alignment, maximizing partnership value, and ultimately delivering transformative therapies to patients.

Speakers:
Jeremy Ahouse, VP of Alliance Management for Pioneering Medicines, 51动漫

Wanda Rutledge-Gordon,听Associate Vice President, Chief Alliance Officer,听Eli Lilly

Peggy Scherle,听Chief Scientific Officer,听Prelude Therapeutics

Risa Shapiro, Head of Alliance Management for Platforms & Early R&D,听Novartis听听

Moderator:听Jake Beverage, VP, Alliance Management,听AbCellera

According to the most recently available figures, more than 2,000 new oncology clinical trials have begun since 2023, demonstrating the continued need for innovative and effective cancer therapies. While many well-known targets have already yielded first-in-class biotherapeutics, the future of precision medicine depends on identifying novel targets and demonstrating - in the clinic - that they can be successfully drugged. This session explores strategies and successes of companies pioneering novel targets and modalities in solid tumors in the clinic. Participants will gain insights into how these candidates were selected and progressed, and the decision-making process involved in evaluating novel agents as monotherapies or as combinations.

Speakers:
, Chief Scientific Officer, Foghorn Therapeutics

Scott A. Armstrong,听Senior Vice President for Drug Discovery & Chief Research Strategy Officer,听Dana-Farber Cancer Institute

Angela Cacace, Chief Scientific Officer, Arvinas

William R. Sellers, Core Institute Member and Cancer Program Director, Broad Institute;听Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School

Jeevan Virk,听Therapeutic Area Strategy Head, Novartis

Moderator: Selina Koch, Executive Editor, Head of Intelligence & Research, BioCentury Inc.

The BIO Storytelling Stage is a showcase of the heart of BIO's priorities鈥攕haring the stories of the biotechnology industry that show who we are, who we serve, what we do, and why we do it. You'll hear inspiring stories from researchers on the newest biotech advancements, perspectives from patients and caregivers on how biotech has affected their lives, and insights from company founders on their relentless pursuit to make the world a better place.

Speakers:, VP, Global Medical Affairs, Rare Disease and Therapeutics,听Moderna

Natalie Kuldell,听Executive Director,听BioBuilder Educational Foundation

Rob Perez,听Founder and Chairman, Life Sciences Cares

Robyn Riseberg, Founder, Boston Community Pediatrics

Silvia Taylor, Executive Vice President, Chief Corporate Affairs & Advocacy Officer,听Novavax

Moderator: Susan Roberts,听Founder,听Roberts Communications

America's biotechnology firms are struggling to attract capital due to political and economic headwinds that threaten to slow the pace of innovation. To address this, the National Security Commission on Emerging Biotechnology recommends at least $15 billion in federal investment over five years that would unlock tens of billions in additional private funding. Smart reforms can reduce investor risk, accelerate commercialization, and strengthen the entire biotechnology ecosystem. This session will examine how targeted tools鈥攍ike seed-stage funds鈥攃an spur private investment and scale up U.S. biotechnology.

Speakers:
Tom DiLenge,听Senior Partner, Global Public Policy, Regulatory & Governmental Strategy, 51动漫

Luciana Borio, Venture Partner, ARCH Venture Partners

Joe Buccina,听Policy and Research Director,听National Security Commission on Emerging Biotechnology (NSCEB)

David Schaffer,听Hubbard Howe Jr. Distinguished Professor of Chemical and Biomolecular Engineering, Bioengineering, Molecular and Cell Biology, University of California at Berkeley

Moderator: Kelly Seagraves,听Vice President, National Security & International Affairs, BIO

Recent data reveals that less than 10% of CEOs in the biopharma industry are women, while female representation in leadership teams stands at 25%. However, the momentum for change is undeniable. A growing number of female leaders are driving innovation and shaping the future of healthcare, demonstrating the powerful impact of women at the forefront of the industry. This panel will spotlight glass shattering female CEOs who are not just leading biotech companies - they are reshaping the future of healthcare. These leaders are leveraging their unique perspectives to foster innovation, develop patient-focused solutions, and push their companies forward in an increasingly competitive industry. Attendees will gain firsthand insights into the pivotal moments and bold decisions that have propelled these leaders to the forefront of biopharma. From startup funding to empowering women in life sciences and tackling gender disparities in research and healthcare, this panel will explore how female-led innovation is transforming healthcare and setting new standards for excellence.

Speakers:

Angela Hwang, CEO-Partner, 51动漫 & CEO, Metaphore

Judy Chou, President and CEO, AltruBio

Elizabeth Jeffords, President & CEO, Iolyx Therapeutics

Sabrina M. Johnson, President and CEO, Dar茅 Bioscience

Daisy Robinton, Co-Founder & CEO, Oviva Therapeutics

Moderator:听Nicole DeFeudis, Editor, Endpoints 51动漫听

Breakthroughs in biomanufacturing, biochemical modeling, and AI-enabled drug discovery and development could dramatically boost industry-wide productivity鈥攂ut they require massive early-stage investments that are currently too risky for many private firms to undertake alone. The NSCEB urges the U.S. government to launch a national research agenda and seed funding effort to tackle "grand challenges" like these.

Speakers:
,听Co-Founder & Chief Technology Officer,听Generate:Biomedicines

Rhys Dubin,听Policy Advisor, Office of the Special Envoy for Critical and Emerging Technology (S/TECH), U.S. Department of State

Steven Moss, Senior Policy Advisor, National Security Commission on Emerging Biotechnology (NSCEB)

Computational methods including AI/machine learning have the potential to be transformational in biopharma by accelerating and enhancing many aspects of drug discovery to bring better drug candidates with a higher likelihood of success to the clinic. Robust data sets are often cited as the limiting factor for this technology. However, less discussed but crucial to the success of computational drug discovery is fostering a new generation of drug hunters with multi-disciplinary training needed to make the best use of these advancements. There may be a shortage of computational chemists and molecular modelers needed to explore the vast array of opportunities that can benefit from computational drug discovery. Hear from a panel of academic and industry leaders that are developing this next-generation, what is most important for them and what our broader ecosystem can do to help fill in the pipeline gaps and ensure we have the people in place to match the technology. This session will focus on the benefits of computational methods, including AI/machine learning, to advance drug discovery, as well as the importance of fostering the next generation of scientists leveraging these vast datasets.

Speakers:
Mickey Atwal,听Chief Data and AI Officer, Pioneering Intelligence, Senior Vice President, Head of Digital for Business, Moderna

Jennifer Chambers, Senior Director of Education, Schr枚dinger

Rebecca Swett, Director, Computational Chemistry, X-Chem

Anna Marie Wagner, Biotech investor, advisor, board member

Moderator: Alex P. Philippidis, Senior Business Editor, GEN

Are the nationalist trends toward investment, trade and national security policies going to divide the world into different spheres of R&D and access to health care products? What impact will they have on global research, cross-border collaboration, and access to healthcare products and public health? The Balkanization of science, knowledge and discovery may have profound impacts on what has traditionally been a collective, global effort.

Speakers:
Michael Nally,听CEO-Partner, 51动漫 & CEO,听Generate:BiomedicinesBibhash Mukhopadhyay,听Venture Capital Investor

Jennifer Sheng,听Head of Healthcare Equity Capital Markets,听Citi

Erika Smith,听CEO,听EpiTET Therapeutics

Moderator: Joseph Damond, Chair, International Trade Policy & Global Life Sciences,听Crowell Global Advisors